 |
BioWorld-International-2003-06-18
Genetic Study Examines Source Of Chimp Virus That Became HIV
Can-Fite Closes $12M Round; CF101 Phase II Trials Planned
ZICHRON YA'AKOV, Israel - Privately held Can-Fite BioPharma Ltd., focused on targeted treatments for cancer and inflammatory diseases, completed a financing round nearing $12 million, at a post-money valuation of $22 million. (BioWorld International)